NasdaqGS:NVAXBiotechs
How Investors May Respond To Novavax (NVAX) Shareholder Revolt Over Pay And Board Governance
At Novavax’s 2026 Annual Meeting, nearly half of shareholders opposed the executive compensation package and there was strong opposition to three Board nominees, prompting its largest shareholder, Shah Capital, to publicly call out management’s operational shortcomings and demand urgent change.
This unusually high level of shareholder pushback shines a light on governance and execution concerns that now sit alongside the company’s scientific and commercial priorities.
With this backdrop of...